NCT06995001View on ClinicalTrials.gov

Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 28, 2024

Primary Completion Date

November 28, 2024

Study Completion Date

November 28, 2024

Conditions

Healthy Volunteers

Interventions

DRUG

SHR-2173

SHR-2173 injection dose 1；

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 2 ；Pacebo dose 2

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 3 ；Pacebo dose 3

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 4 ；Pacebo dose 4

DRUG

SHR-2173 ；Placebo

SHR-2173 injection dose 5 ；Pacebo dose 5

Trial Locations (1)

570208

Haikou People's Hospital, Haikou

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06995001 - Phase I Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Injection of SHR-2173 in Healthy Subjects | Biotech Hunter | Biotech Hunter